Christina M. Annunziata Women's Malignancies Branch National Cancer Institute Biography Publications Institution JoVE Articles Christina M. Annunziata has not added a biography. If you are Christina M. Annunziata and would like to personalize this page please email our Author Liaison for assistance. Publications Loss of Compensatory Pro-survival and Anti-apoptotic Modulator, IKKε, Sensitizes Ovarian Cancer Cells to CHEK1 Loss Through an Increased Level of P21 Oncotarget. Dec, 2014 | Pubmed ID: 25474241 The Small Molecule NSC676914A is Cytotoxic and Differentially Affects NFκB Signaling in Ovarian Cancer Cells and HEK293 Cells Cancer Cell International. 2014 | Pubmed ID: 25324692 Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-associated Breast or Ovarian Cancer with Biomarker Analyses Journal of the National Cancer Institute. Jun, 2014 | Pubmed ID: 24842883 Pathway-specific Engineered Mouse Allograft Models Functionally Recapitulate Human Serous Epithelial Ovarian Cancer PloS One. 2014 | Pubmed ID: 24748377 A Phase II Clinical Trial of Polyethylene Glycol-conjugated L-asparaginase in Patients with Advanced Ovarian Cancer: Early Closure for Safety Molecular and Clinical Oncology. May, 2013 | Pubmed ID: 24649212 Novel Facts About FAK: New Connections to Drug Resistance? Journal of the National Cancer Institute. Oct, 2013 | Pubmed ID: 24062526 Translational Predictive Biomarker Analysis of the Phase 1b Sorafenib and Bevacizumab Study Expansion Cohort Molecular & Cellular Proteomics : MCP. Jun, 2013 | Pubmed ID: 23449826 Evolutionarily Conserved Protein ERH Controls CENP-E MRNA Splicing and is Required for the Survival of KRAS Mutant Cancer Cells Proceedings of the National Academy of Sciences of the United States of America. Dec, 2012 | Pubmed ID: 23236152 IKK-ε Coordinates Invasion and Metastasis of Ovarian Cancer Cancer Research. Nov, 2012 | Pubmed ID: 22942254 Phase 1, Open-label Study of MEDI-547 in Patients with Relapsed or Refractory Solid Tumors Investigational New Drugs. Feb, 2012 | Pubmed ID: 22370972 Targeting the Proteasome with Bortezomib in Multiple Myeloma: Update on Therapeutic Benefit As an Upfront Single Agent, Induction Regimen for Stem-cell Transplantation and As Maintenance Therapy American Journal of Therapeutics. Mar, 2012 | Pubmed ID: 21248621 A Mechanistic Rationale for MEK Inhibitor Therapy in Myeloma Based on Blockade of MAF Oncogene Expression Blood. Feb, 2011 | Pubmed ID: 21163924 PARP Inhibitors in BRCA1/BRCA2 Germline Mutation Carriers with Ovarian and Breast Cancer F1000 Biology Reports. 2010 | Pubmed ID: 20948822 Poly (ADP-ribose) Polymerase As a Novel Therapeutic Target in Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Sep, 2010 | Pubmed ID: 20823142 CD157 in Ovarian Carcinoma: How Does It Help Us? Journal of the National Cancer Institute. Aug, 2010 | Pubmed ID: 20639477 Nuclear Factor KappaB Transcription Factors Are Coexpressed and Convey a Poor Outcome in Ovarian Cancer Cancer. Jul, 2010 | Pubmed ID: 20564628 Activation of NF-kappaB Signaling by Inhibitor of NF-kappaB Kinase Beta Increases Aggressiveness of Ovarian Cancer Cancer Research. May, 2010 | Pubmed ID: 20424119 Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity As Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jan, 2010 | Pubmed ID: 20068097 The Sumoylation Pathway is Dysregulated in Multiple Myeloma and is Associated with Adverse Patient Outcome Blood. Apr, 2010 | Pubmed ID: 19965618 Uterine Papillary Serous Carcinoma: a New Paradigm for Treatment? Cancer. Aug, 2009 | Pubmed ID: 19452535 Combination Targeted Therapy with Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Aug, 2008 | Pubmed ID: 18669456 Lack of Reliability of CA125 Response Criteria with Anti-VEGF Molecularly Targeted Therapy Cancer. Apr, 2008 | Pubmed ID: 18300236 BAG-4/SODD and Associated Antiapoptotic Proteins Are Linked to Aggressiveness of Epithelial Ovarian Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2007 | Pubmed ID: 18006758 Frequent Engagement of the Classical and Alternative NF-kappaB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma Cancer Cell. Aug, 2007 | Pubmed ID: 17692804 Proteomics in Clinical Trials and Practice: Present Uses and Future Promise Molecular & Cellular Proteomics : MCP. Oct, 2006 | Pubmed ID: 16737951 Is There a Genomic Basis for Primary Chemoresistance in Ovarian Cancer? Gynecologic Oncology. Jul, 2003 | Pubmed ID: 12821333 डिम्बग्रंथि के कैंसर के ट्यूमर शुरुआत कोशिकाओं की इन विट्रो संवर्धन में Carrie D. House1, Lidia Hernandez1, Christina M. Annunziata1 1Women's Malignancies Branch, National Cancer Institute Medicine
डिम्बग्रंथि के कैंसर के ट्यूमर शुरुआत कोशिकाओं की इन विट्रो संवर्धन में Carrie D. House1, Lidia Hernandez1, Christina M. Annunziata1 1Women's Malignancies Branch, National Cancer Institute Medicine